Gilead reports trial success. Gilead Sciences stock is valued at USD 189.8 billion gradually

Published on 10/20/2026 at 11:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Response reached 66 percent versus 37 percent on placebo. Gilead Sciences stock costs EUR 137.34 on October 20, 2026, 0.10 percent below Xetra close.

Clinical data and reporting date

Emvistegrast produced a 66 percent clinical response versus 37 percent for placebo on October 19, 2026.
Clinical remission reached 31 percent with emvistegrast versus 8 percent with placebo after 12 weeks.
Gilead Sciences stock traded at EUR 137.34 at 11:08 a.m. CEST at Lang & Schwarz on October 20, 2026, 0.10 percent below the Xetra close of October 19, 2026.

Bauhaus-Poster BIOTECH mit geometrischen Formen und Primärfarben für Gilead Sciences — Gilead Sciences Bauhaus-Poster ISIN US3755581036 geometrisch BIOTECH Primärfarben Konstruktivismus medizinisches Kreuz Design, Illustration mit AI erstellt.

Gilead Sciences stock (ISIN US3755581036) was trading at EUR 137.34 at Lang & Schwarz on October 20, 2026, 0.10 percent below the Xetra close of October 19, 2026 at EUR 137.48. On October 19, 2026, Gilead reported positive Phase 2 results for its oral emvistegrast treatment in ulcerative colitis, according to Gilead Sciences.

Three milestones shape the pipeline

On August 4, 2026, second-quarter total product sales reached USD 7.60 billion, up 8 percent year over year, according to the Yahoo Finance transcript. On October 15, 2026, Gilead announced that third-quarter results and guidance would be released on October 29, 2026. The company then reported the emvistegrast response data on October 19, 2026, making the inflammation pipeline the latest quantified catalyst.

The trial enrolled 238 adults and tested three doses against placebo. At Week 12, the 200 mg dose produced a 66 percent clinical response rate versus 37 percent for placebo, while clinical remission reached 31 percent versus 8 percent, according to Reuters. The study remains ongoing, and Gilead plans to initiate a Phase 3 monotherapy study in 2027.

What does 66 percent response mean?

The result gives Gilead an oral candidate in a validated inflammatory bowel disease pathway, but it remains an investigational program. The company said adverse events occurred in 36 percent of emvistegrast-treated participants and 37 percent of placebo participants, while the study release cautioned that safety and efficacy have not been established.

When are the next results due?

Gilead's next scheduled reporting event is October 29, 2026, after the market closes, with management's webcast set for 4:30 p.m. ET, according to Gilead Sciences. Investors will have a fresh test of commercial performance alongside the pipeline update.

Stock holds near its yearly high

Gilead's primary listing is Nasdaq, where the stock closed at USD 153.07 on October 19, 2026. The finance snapshot put market capitalization at USD 189.8 billion and the 52-week range at USD 114.02 to USD 160.51 as of that date. At Lang & Schwarz, the stock was trading at EUR 137.34 on October 20, 2026 at 11:08 a.m. CEST, 0.10 percent below the Xetra close of October 19, 2026 at EUR 137.48. The further course of trading is shown by the continuously updated real-time quote of Gilead Sciences stock.